Develops drugs for aplastic anemia and breast cancer.
Jun 2026Revenue $237K/yrExpenses $1.04M/yr
No trendCash runway ≈ 1 months from Jun 2026
Figures by year
When will Regen BioPharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $237K and expenses $1.04M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $237K | $575K | −$339K |
| Sep 2024 | $237K | $654K | −$417K |
| Sep 2023 | $237K | $924K | −$687K |
| Sep 2022 | $126K | $465K | −$340K |
| Sep 2021 | $61.2K | $262K | −$201K |
| Sep 2020 | $110K | $319K | −$209K |
| Sep 2019 | $110K | $867K | −$757K |
| Sep 2018 | $100K | $1.53M | −$1.43M |
| Sep 2017 | $110K | $2.62M | −$2.51M |
| Sep 2016 | $100K | $3.06M | −$2.96M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.